ARS Pharmaceuticals Inc (NASDAQ:SPRY) shares, rose in value on Wednesday, March 26, with the stock price down by -4.18% to the previous day’s close as strong demand from buyers drove the stock to $12.60.
Actively observing the price movement in the last trading, the stock closed the session at $13.15, falling within a range of $12.31 and $13.2. The value of beta (5-year monthly) was 1.411 whereas the PE ratio was 164.28 over 12-month period. Referring to stock’s 52-week performance, its high was $18.51, and the low was $7.55. On the whole, SPRY has fluctuated by 19.32% over the past month.
With the market capitalization of ARS Pharmaceuticals Inc currently standing at about $1.24 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-19.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 83.11M, with a low estimate of 5M and a high estimate of 8.5M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 7.48M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SPRY’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the PEG ratio is about 3.75, with the price of SPRY currently trading nearly 8.48% and 3.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.46, while the 7-day volatility ratio is showing 11.67% which for the 30-day chart, stands at 7.50%. Furthermore, ARS Pharmaceuticals Inc (SPRY)’s beta value is 0.91, and its average true range (ATR) is 0.93.
A comparison of ARS Pharmaceuticals Inc (SPRY) with its peers suggests the former has fared considerably weaker in the market. SPRY showed an intraday change of -4.18% in last session, and over the past year, it grew by 45.66%%.
Data on historical trading for ARS Pharmaceuticals Inc (NASDAQ:SPRY) indicates that the trading volumes over the past 10 days have averaged 2.56 and over the past 3 months, they’ve averaged 1.56 million. According to company’s latest data on outstanding shares, there are 97.95 million shares outstanding.
Nearly 47.22% of ARS Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 50.53% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 19.43 million shares as on 2025-03-14, resulting in a short ratio of 15.06. According to the data, the short interest in ARS Pharmaceuticals Inc (SPRY) stood at 3704.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 16.48 million. The stock has risen by 19.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SPRY stock heading into the next quarter.
